subscribeSubscribe
Par Pharma recalls blood pressure med for possible contamination

Par Pharma recalls blood pressure med for possible contamination
Joseph Keenan FIERCE PHARMA
22 Apr 2024
Share Share
Enforcement Report - Week of April 3, 2024

Enforcement Report - Week of April 3, 2024
FDA
03 Apr 2024
Share Share
Courts clear FDA to approve Liquidia`s PAH drug Yutrepia

Courts clear FDA to approve Liquidia`s PAH drug Yutrepia
Kevin Dunleavy FIERCE PHARMA
02 Apr 2024
Share Share
Par Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection

Par Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection
PR NEWSWIRE
12 Mar 2024
Share Share
Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution

Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
FDA
12 Mar 2024
Share Share
United Therapeutics starts litigation with FDA over rival Liquidia`s drug application

United Therapeutics starts litigation with FDA over rival Liquidia`s drug application
REUTERS
22 Feb 2024
Share Share
Actavis`s Generic Treprostinil Approval in the U.S.

Actavis`s Generic Treprostinil Approval in the U.S.
FDA
03 Apr 2023
Share Share
Liquidia Announces Collaboration to Develop a New Infusion Pump of Treprostinil

Liquidia Announces Collaboration to Develop a New Infusion Pump of Treprostinil
GLOBENEWSWIRE
05 Dec 2022
Share Share
United Therapeutics Announces Data From the EXPEDITE Study of Remodulin

United Therapeutics Announces Data From the EXPEDITE Study of Remodulin
BUSINESSWIRE
31 Oct 2022
Share Share
United Announces First Patient Enrolled in Phase 3 TETON 2 Study of Tyvaso

United Announces First Patient Enrolled in Phase 3 TETON 2 Study of Tyvaso
BUSINESSWIRE
11 Oct 2022
Share Share